

Excalipoint Therapeutics launches with \$68.7 M to develop next-gen T-cell engager therapies in China

19 March 2026 | News

One of the largest seed financing rounds for a Chinese biotechnology company



China-based startup Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, has announced an oversubscribed \$68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs.

The financing includes \$41 million in seed funding completed at the company's inception in August 2025, co-led by HSG, Apricot Capital, and Yuanbio Venture Capital, with participation from 5Y Capital, Co-Win Ventures, Med-Fine Capital and Hony Capital. The seed round represents one of the largest early-stage financings for a Chinese biotechnology company.

After ramping up to full operational status and achieving significant clinical progress in just six months, the company secured a \$27.7 million extension round co-led by MPCi (formerly Matrix Partners China) and Centurium Capital. The round also included significant participation from global investors LAV (Lilly Asia Ventures) and Eisai Innovation Inc, the venture arm of Eisai Co., Ltd. Existing investors Apricot Capital and 5Y Capital also participated in the extension round.

The new funding will support advancement of Excalipoint's proprietary platforms - TOPAbody, T-Cell Immune Shield, and TCE Probody - as well as a pipeline of six differentiated programmes with first- or best-in-class potential. These programs are designed to improve the efficacy, safety, and durability of T-cell immunotherapies for solid tumors and other difficult-to-treat cancers.